Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with amyotrophic lateral sclerosis (ALS) Denali to receive a milestone payment of $40 million from ...
Zentalis Pharmaceuticals, Inc. announced that the first patient has been dosed in Part 2A of the DENALI Phase 2 clinical trial, which evaluates the efficacy of azenosertib for patients with Cyclin E1+ ...
Camp Denali, located at the 89-mile marker in Denali National Park, will reopen on June 2. The family-owned and operated lodge since 1952 has announced its 2023 summer speaker series, wildlife ...
Denali Therapeutics Inc (NASDAQ:DNLI) shares are moving lower in Thursday’s after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. In the company’s ...
SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...
Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback